DUBAI, United Arab Emirates, Dec. 10, 2025 (GLOBE NEWSWIRE) — Mutuum Finance (MUTM), a rising project in the DeFi crypto sector, is reporting continued progress across the development roadmap as funding approaches a major threshold. With steady technical updates and strong user participation, the project is entering one of its busiest periods ahead of its […]
(NASDAQ:JG), SHENZHEN, China, Dec. 10, 2025 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that EngageLab, its leading omni-channel customer engagement platform, launched its new behavioral CAPTCHA solution, expanding its portfolio of digital engagement and security
(NasdaqGM:MDWD), MediWound Reports New Clinical Data Demonstrating NexoBrid(R)'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries Prospective clinical data show NexoBrid(R) removes embedded particles in friction and blast wounds, reducing pigmented wound surface by >90% Traumatic tattoos form when dirt, metal, or explosive residue becomes permanently embedded in the skin; findings support further
(TSX:UNI),(Pinksheets:USYNF),(PinkSheets:USYNF), TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) — Unisync Corp. (“Unisync”) (TSX:”UNI”) (OTC:”USYNF“) today announced its financial results for the twelve months ended September 30, 2025, highlighted by a return to profitability, a second consecutive year of gross margin improvement, and a growing base of contracted new business. For fiscal 2025, Unisync posted $1.5 million
(AUST:TLX.AX),(NasdaqGM:TLX), MELBOURNE, Australia and PALO ALTO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix's theranostic products and external beam radiation therapy (EBRT).
Higher-grade, Cu-Au starter pit for Costa Fuego materialising https://mma.prnewswire.com/media/2842262/Hot_Chili_Limited_Drilling_Confirms_Large__Higher_Grade_Core_fro.jpg Highlights — Two diamond drill holes have visually recorded wide intersections of strong copper porphyry style mineralisation fromnear-surface- outlining a potentially significantup-dip expansion to La Verde's gold-rich, higher-grade core, results pending — In addition, latest assay results from Phase two drilling at La Verde (DKP005D) have
(NASDAQ:ALMU), GOLETA, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) — Aeluma, Inc. (NASDAQ: ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum computing, announced today that its CEO, Jonathan Klamkin, Ph.D., and CFO, Christopher Stewart, will participate in a fireside chat hosted by Benchmark Company
(PinkSheets:BSEM),(Pinksheets:BSEM), POMPANO BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today announced the launch of a new product line, American Amnion, at the Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference held in Phoenix, Arizona, on December
$47.5 million Series A financing led by Samsara Biocapital and Lightstone Ventures to advance PsiThera's growing pipeline, starting with multiple clinically validated TNF superfamily preclinical programs Biotech veteran Eric Shaff appointed CEO and joins established leadership team, including Woody Sherman, Ph.D., Founder and Chief Innovation Officer, and Camil Sayegh, Ph.D., Chief Scientific Officer PsiThera's scientific
(TSX:MBX),(OTC US:MBXBF),(Other OTC:MBXBF), MISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix(R)), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QAPs(TM) quality assessment products and availability of QUANTDx(TM) reference materials to support antigen or molecular tests for H3N2 strains of seasonal Influenza A (a.k.a.,